Skip to main content
main-content

Diabetes complications and comorbidities

Highlights

01-14-2019 | Mental health | medwireNews | News

High mental illness burden in young-onset type 2 diabetes

Over a third of time spent in hospital before the age of 40 years by patients who develop type 2 diabetes by this age is due to mental illness, report researchers.

Source:

Ann Intern Med 2019; doi:10.7326/M18-1900

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

Source:

Ann Intern Med 2019; doi:10.7326/M18-0567
Ann Intern Med 2019; doi:10.7326/M18-3550

12-14-2018 | Risk factors | Feature | Article

Sleep duration: Waking up to a major metabolic risk factor

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1812389

10-22-2018 | Mental health | Highlight | News

Insulin manipulation strongly linked to psychiatric comorbidity

Insulin manipulation, the practice of deliberately under- or overdosing insulin, is strongly associated with psychiatric comorbidity in children and young adults with type 1 diabetes, Austrian research shows.

Source:

Pediatr Diabetes 2018; doi:10.1111/pedi.12784

10-05-2018 | Hyperglycemia | EASD 2018 | News

ADA/EASD consensus report on managing hyperglycemia in type 2 diabetes published

The final version of the 2018 update to the consensus guidelines on managing hyperglycemia in people with type 2 diabetes is now published.

Source:

Diabetologia 2018; doi:10.1007/s00125-018-4729-5
Diabetes Care 2018; doi:10.2337/dci18-0033
EASD Annual Meeting; Berlin, Germany: 1–5 October 2018

10-04-2018 | Empagliflozin | EASD 2018 | News

EASE: Add-on empagliflozin improves glycemic control in type 1 diabetes

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

Source:

Diabetes Care 2018; doi:10.2337/dc18-1749
EASD Annual Meeting; Berlin, Germany: 1–5 October 2018

09-24-2018 | Diabetic foot ulcers | medwireNews | News

LeucoPatch improves healing of difficult diabetic foot ulcers

Weekly application of an autologous immune cell, fibrin, and platelet patch significantly increases the rate of healing of hard-to-heal foot ulcers compared with standard care in people with diabetes, randomized trial data show.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/ S2213-8587(18)30240-7

09-18-2018 | Sexual dysfunction | View from the clinic | Article

Regaining sexual health in diabetes: Start with open communication

Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes.

Author:
Clipper Young

09-05-2018 | Diagnosis | Case study | Article

Acute illness while on a SGLT2 inhibitor and ketogenic diet

Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

Author:
Theresa Smyth

08-29-2018 | Blood glucose monitoring | Editorial | Article

The ambulatory glucose profile: What, why, and how?

Editorial Board member Lori Berard discusses how the ambulatory glucose profile is quietly revolutionizing the analysis of blood glucose and glycemic control for patients and practitioners.

Author:
Lori Berard

08-26-2018 | Lorcaserin | Highlight | News

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1808721
N Engl J Med 2018; doi:10.1056/NEJMe1810855

08-18-2018 | Continuous glucose monitoring | Review | Article

Prevention and management of severe hypoglycemia and hypoglycemia unawareness: Incorporating sensor technology

Lucidi P et al. Curr Diab Rep 2018; 18: 83. doi: 10.1007/s11892-018-1065-6

08-15-2018 | SGLT2 inhibitors | Highlight | News

Research adds to SGLT2 inhibitor amputation risk debate

Researchers have found evidence to support an increased risk for amputation among patients with type 2 diabetes taking sodium-glucose cotransporter 2 inhibitors relative to some oral treatments.

Source:

JAMA Int Med 2018; doi:10.1001/jamainternmed.2018.3034
JAMA Int Med 2018; doi:10.1001/jamainternmed.2018.3025

08-15-2018 | Neuropathy | Editorial | Article

Are we using the right tests to diagnose diabetic neuropathy?

Uazman Alam and colleagues interrogate current evidence and real-world clinical scenarios to address whether enough is being done with the tools available to screen and diagnose diabetic neuropathy.

Authors:
Shazli Azmi, Andrew Marshall, Andrew Nelson, Uazman Alam

08-06-2018 | Metabolic surgery | Highlight | News

Real-world bariatric surgery data show microvascular protection

Obese patients with type 2 diabetes who undergo bariatric surgery achieve large reductions in their risk for microvascular complications, shows a real-world study.

Source:

Ann Intern Med 2018; doi:10.7326/M17-2383

07-18-2018 | Sulfonylureas | Highlight | News

Continuing metformin advisable for patients starting sulfonylurea treatment

Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.

Source:

BMJ 2018; 362: k2693, k3041

06-29-2018 | Canagliflozin | Highlight | News

OBSERVE-4D: Canagliflozin amputation risk not replicated in real-world data

A study of patients from US administrative claims databases finds no evidence that use of canagliflozin increases the risk for below the knee amputation when compared with other sodium-glucose cotransporter 2 inhibitors or with other antidiabetic medications.

Source:

Diabetes Obes Metab 2018; Advance online publication

06-22-2018 | Hypertension | Review | Article

The optimal blood pressure target in diabetes mellitus: A quest coming to an end?

Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

06-21-2018 | Sleep disorders | Article

Relationship between sleep disturbance and self-care in adults with type 2 diabetes

Zhu B et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1181-4

image credits